MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Li, Jingwen; Meng, Tao; Yuan, Ming; Wen, Liang; Cheng, Bolin; Liu, Na; Huang, Xuan; Hong, Yun; Yuan, Hong; Hu, Fuqiang

doi:10.2147/ijn.s111647

Cited by 72 publications

(38 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While proportions of miRNA:ST 1:10 rendered cationic nanosystems, an inversion on the zeta potential was reported for formulations prepared with the two lower proportions of ST (miRNA:ST 1:1 and 1:2.5). Sizes ranging from 150 to 180nm, and low polydispersity indexes, were reported in all cases except for the ratios miRNA:ST 1:5 and 1:7.5, for which a massive precipitation was observed, most probably due to the neutralization of the surface charge, as reported for other types of RNA/DNA-loaded nanosystems in which preparation relies on the establishment of electrostatic interactions [34,35]. Table 2.…”

Section: Of 16supporting

confidence: 59%

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

et al. 2020

View full text Add to dashboard Cite

Gene replacement therapy with oncosuppressor microRNAs (miRNAs) is a promising alternative to interfere with cancer progression. However, miRNAs are highly inefficient in a biological environment, hampering a successful translation to clinics. Nanotechnology can tackle this drawback by providing delivery systems able to efficiently deliver them to cancer cells. Thus, the objective of this work was to develop biocompatible nanosystems based on sphingomyelin (SM) for the intracellular delivery of miRNAs to colorectal cancer cells. We pursued two different approaches to select the most appropriate composition for miRNA delivery. On the one hand, we prepared sphingomyelin-based nanosystems (SNs) that incorporate the cationic lipid stearylamine (ST) to support the association of miRNA by the establishment of electrostatic interactions (SNs–ST). On the other hand, the cationic surfactant (DOTAP) was used to preform lipidic complexes with miRNA (Lpx), which were further encapsulated into SNs (SNs-Lpx). Restitution of miRNA145 levels after transfection with SNs-Lpx was related to the strongest anticancer effect in terms of tumor proliferation, colony forming, and migration capacity assays. Altogether, our results suggest that SNs have the potential for miRNA delivery to develop innovative anticancer therapies.

show abstract

Section: Of 16supporting

confidence: 59%

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Many such strategies are being developed [ 222 , 223 ]. For example, delivery of lipid nanoparticles containing miR-200c combined with paclitaxel (PTX) into breast CSCs exhibits profound anti-tumor activity [ 224 ].…”

Section: Targeting Lipid Metabolism As Novel Therapeutic Strategies Amentioning

confidence: 99%

Emerging role of lipid metabolism alterations in Cancer stem cells

Man

Chen

et al. 2018

J Exp Clin Cancer Res

165

130

View full text Add to dashboard Cite

BackgroundCancer stem cells (CSCs) or tumor-initiating cells (TICs) represent a small population of cancer cells with self-renewal and tumor-initiating properties. Unlike the bulk of tumor cells, CSCs or TICs are refractory to traditional therapy and are responsible for relapse or disease recurrence in cancer patients. Stem cells have distinct metabolic properties compared to differentiated cells, and metabolic rewiring contributes to self-renewal and stemness maintenance in CSCs.Main bodyRecent advances in metabolomic detection, particularly in hyperspectral-stimulated raman scattering microscopy, have expanded our knowledge of the contribution of lipid metabolism to the generation and maintenance of CSCs. Alterations in lipid uptake, de novo lipogenesis, lipid droplets, lipid desaturation, and fatty acid oxidation are all clearly implicated in CSCs regulation. Alterations on lipid metabolism not only satisfies the energy demands and biomass production of CSCs, but also contributes to the activation of several important oncogenic signaling pathways, including Wnt/β-catenin and Hippo/YAP signaling. In this review, we summarize the current progress in this attractive field and describe some recent therapeutic agents specifically targeting CSCs based on their modulation of lipid metabolism.ConclusionIncreased reliance on lipid metabolism makes it a promising therapeutic strategy to eliminate CSCs. Targeting key players of fatty acids metabolism shows promising to anti-CSCs and tumor prevention effects.

show abstract

“…Here we present data supporting the innovative role of treatment with miRNAs in combination with drug in breast cancer. Some studies focused on the effects of miRNA in combination with one or few drugs (Liu et al, 2016 ; Rui et al, 2017 ; Strumidło et al, 2017 ). In our study, we tested 14 drugs, on different subtypes of breast cancer cell lines, in combination with candidate miRNAs.…”

Section: Discussionmentioning

confidence: 99%

Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors

et al. 2018

View full text Add to dashboard Cite

Background: Breast cancer (BC) represents the most common cancer in women worldwide. Due to its heterogeneous nature, breast cancer management might benefit from differential treatments toward personalized medicine. Additionally, drug resistance is a common phenomenon. We systematically investigated the effect of 14 different drugs administered on BC cell lines in combination with microRNAs (miRNA, miR).Methods: Thirty-eight miRNAs, all associated with BC by clinical and molecular parameters including progression, prognosis and subtypes, were tested for their effects on the viability of 12 different BC cell lines. Four miRNAs with the strongest impact on viability were further assayed in combination with 14 BC drugs. Mann–Whitney U-test with Bonferroni correction was used for statistical analysis.Results: In a miRNA only pre-screen we observed effects on BC cell lines' viability for 34 out of 38 candidate miRNAs. We then identified 14 miRNA/drug combinations for which the combination IC50 was lower than that of both miRNA and drug as single agents. miR-181a, paired with GSK1070916, Doxorubicin, XL765 and AMG511, was the only miRNA active on the triple negative (TNBC) MDA-MB-468 cell line. miR-126 was the only miRNA (in combination with CDK4/6 or PIK3CA inhibitors) with significant effects on cell lines from different subtypes: MCF7 (Luminal) and MDA-MB-453 (HER2+). Because of its activity on different BC subtypes, we investigated the genome wide effects of miR-126 using transcriptomics and confirmed that expression of miR-126 in BC cell lines affected cell cycle and mitosis.Conclusion: Our results show that a combination treatment with miRNAs, in particular miR-181a, miR-326, miR-9 and miR-126, enhance the activity of specific BC drugs in vitro, even on the most aggressive BC subtypes, HER2+ and TNBC. Finally, as expected from its drug interactions, based on a whole transcriptome study we could confirm a role for miR-126 in cell cycle regulation.

show abstract

MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Cited by 72 publications

References 33 publications

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

Emerging role of lipid metabolism alterations in Cancer stem cells

Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors

Contact Info

Product

Resources

About